Leerink Partners has increased its price target for Revolution Medicines Inc. (NASDAQ: RVMD) from $115 to $147, maintaining an Outperform rating after the company reported positive results from its Phase III RASolute 302 clinical trial. The trial evaluated daraxonrasib for second-line treatment of pancreatic ductal adenocarcinoma, demonstrating a median overall survival of 13.2 months compared to 6.7 months for standard chemotherapy. This significant improvement is underscored by a hazard ratio of 0.40 and a p-value of less than 0.0001. The stock has surged to $131.47, nearing its 52-week high, and has increased by 170% over the past year. Other analysts, including Raymond James and Mizuho, have also raised their price targets, indicating strong market confidence in Revolution Medicines' pipeline. The company plans to submit its data to global regulatory authorities, including the FDA, and present additional findings at the American Society of Clinical Oncology 2026 Annual Meeting.